Literature DB >> 25992285

Cancer-associated muscle weakness: What's bone got to do with it?

David L Waning1, Theresa A Guise1.   

Abstract

Cancer-associated muscle weakness is an important paraneoplastic syndrome for which there is currently no treatment. Tumor cells commonly metastasize to bone in advanced cancer to disrupt normal bone remodeling and result in morbidity that includes muscle weakness. Tumor in bone stimulates excessive osteoclast activity, which causes the release of growth factors stored in the mineralized bone matrix. These factors fuel a feed-forward vicious cycle of tumor growth in bone and bone destruction. Recent evidence indicates that these bone-derived growth factors can act systemically to cause muscle weakness. Muscle weakness can be caused by reduced muscle mass or reduced muscle function; in advanced disease, it is likely due to a combination of both reduced quantity and quality of muscle. In this review, we discuss possible mechanisms that lead to skeletal muscle weakness due to bone metastases.

Entities:  

Year:  2015        PMID: 25992285      PMCID: PMC4432780          DOI: 10.1038/bonekey.2015.59

Source DB:  PubMed          Journal:  Bonekey Rep        ISSN: 2047-6396


  65 in total

1.  PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts.

Authors:  S O Marx; S Reiken; Y Hisamatsu; T Jayaraman; D Burkhoff; N Rosemblit; A R Marks
Journal:  Cell       Date:  2000-05-12       Impact factor: 41.582

2.  Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival.

Authors:  Xiaolan Zhou; Jin Lin Wang; John Lu; Yanping Song; Keith S Kwak; Qingsheng Jiao; Robert Rosenfeld; Qing Chen; Thomas Boone; W Scott Simonet; David L Lacey; Alfred L Goldberg; H Q Han
Journal:  Cell       Date:  2010-08-20       Impact factor: 41.582

3.  Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway.

Authors:  Yibin Kang; Wei He; Shaun Tulley; Gaorav P Gupta; Inna Serganova; Chang-Rung Chen; Katia Manova-Todorova; Ronald Blasberg; William L Gerald; Joan Massagué
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-19       Impact factor: 11.205

4.  Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy.

Authors:  Emidio E Pistilli; Sasha Bogdanovich; Marcus D Goncalves; Rexford S Ahima; Jennifer Lachey; Jasbir Seehra; Tejvir Khurana
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

5.  Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging.

Authors:  Daniel C Andersson; Matthew J Betzenhauser; Steven Reiken; Albano C Meli; Alisa Umanskaya; Wenjun Xie; Takayuki Shiomi; Ran Zalk; Alain Lacampagne; Andrew R Marks
Journal:  Cell Metab       Date:  2011-08-03       Impact factor: 27.287

Review 6.  Involvement of activin in the regulation of bone metabolism.

Authors:  R Sakai; Y Eto
Journal:  Mol Cell Endocrinol       Date:  2001-06-30       Impact factor: 4.102

7.  Circulating levels of IGF-1 directly regulate bone growth and density.

Authors:  Shoshana Yakar; Clifford J Rosen; Wesley G Beamer; Cheryl L Ackert-Bicknell; Yiping Wu; Jun-Li Liu; Guck T Ooi; Jennifer Setser; Jan Frystyk; Yves R Boisclair; Derek LeRoith
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

8.  BMP signaling controls muscle mass.

Authors:  Roberta Sartori; Elija Schirwis; Bert Blaauw; Sergia Bortolanza; Jinghui Zhao; Elena Enzo; Amalia Stantzou; Etienne Mouisel; Luana Toniolo; Arnaud Ferry; Sigmar Stricker; Alfred L Goldberg; Sirio Dupont; Stefano Piccolo; Helge Amthor; Marco Sandri
Journal:  Nat Genet       Date:  2013-09-29       Impact factor: 38.330

9.  Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment.

Authors:  Lauren K Dunn; Khalid S Mohammad; Pierrick G J Fournier; C Ryan McKenna; Holly W Davis; Maria Niewolna; Xiang Hong Peng; John M Chirgwin; Theresa A Guise
Journal:  PLoS One       Date:  2009-09-03       Impact factor: 3.240

10.  Estimation of Cachexia among Cancer Patients Based on Four Definitions.

Authors:  Kathleen M Fox; John M Brooks; Shravanthi R Gandra; Richard Markus; Chiun-Fang Chiou
Journal:  J Oncol       Date:  2009-07-01       Impact factor: 4.375

View more
  17 in total

Review 1.  Bone Pain and Muscle Weakness in Cancer Patients.

Authors:  Daniel P Milgrom; Neha L Lad; Leonidas G Koniaris; Teresa A Zimmers
Journal:  Curr Osteoporos Rep       Date:  2017-04       Impact factor: 5.096

2.  Parallel mechanisms suppress cochlear bone remodeling to protect hearing.

Authors:  Emmanuel J Jáuregui; Omar Akil; Claire Acevedo; Faith Hall-Glenn; Betty S Tsai; Hrishikesh A Bale; Ellen Liebenberg; Mary Beth Humphrey; Robert O Ritchie; Lawrence R Lustig; Tamara Alliston
Journal:  Bone       Date:  2016-04-13       Impact factor: 4.398

3.  Soluble activin receptor type IIB decoy receptor differentially impacts murine osteogenesis imperfecta muscle function.

Authors:  Youngjae Jeong; Salah A Daghlas; Alp S Kahveci; Daniel Salamango; Bettina A Gentry; Marybeth Brown; R Scott Rector; R Scott Pearsall; Charlotte L Phillips
Journal:  Muscle Nerve       Date:  2017-06-15       Impact factor: 3.217

Review 4.  Reactive Oxygen Species/Nitric Oxide Mediated Inter-Organ Communication in Skeletal Muscle Wasting Diseases.

Authors:  Lucia M Leitner; Rebecca J Wilson; Zhen Yan; Axel Gödecke
Journal:  Antioxid Redox Signal       Date:  2017-01-04       Impact factor: 8.401

5.  Minocycline attenuates cardiac dysfunction in tumor-burdened mice.

Authors:  Raymond D Devine; Clayton M Eichenseer; Loren E Wold
Journal:  J Mol Cell Cardiol       Date:  2016-09-20       Impact factor: 5.000

Review 6.  The calcium-sensing receptor as a mediator of inflammation.

Authors:  Gordon L Klein; Shawn M Castro; Roberto P Garofalo
Journal:  Semin Cell Dev Biol       Date:  2015-08-21       Impact factor: 7.727

Review 7.  Advances in cancer cachexia: Intersection between affected organs, mediators, and pharmacological interventions.

Authors:  Jawed A Siddiqui; Ramesh Pothuraju; Maneesh Jain; Surinder K Batra; Mohd W Nasser
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-03-25       Impact factor: 10.680

8.  An analysis of the relationship between metastases and cachexia in lung cancer patients.

Authors:  Masatoshi Shiono; Kan Huang; Robert J Downey; Nikita Consul; Nicolas Villanueva; Kristen Beck; Kathleen Fenn; Donald Dietz; Takuhiro Yamaguchi; Shunsuke Kato; Chaitanya Divgi; Kevin Kalinsky; Ying Wei; Yuan Zhang; Alain C Borczuk; Akira Inoue; Balazs Halmos; Swarnali Acharyya
Journal:  Cancer Med       Date:  2016-08-03       Impact factor: 4.452

9.  Osteolytic Breast Cancer Causes Skeletal Muscle Weakness in an Immunocompetent Syngeneic Mouse Model.

Authors:  Jenna N Regan; Carter Mikesell; Steven Reiken; Haifang Xu; Andrew R Marks; Khalid S Mohammad; Theresa A Guise; David L Waning
Journal:  Front Endocrinol (Lausanne)       Date:  2017-12-19       Impact factor: 5.555

10.  Monitoring Metastasis and Cachexia in a Patient with Breast Cancer: A Case Study.

Authors:  Nikita Consul; Xiaotao Guo; Courtney Coker; Sara Lopez-Pintado; Hanina Hibshoosh; Binsheng Zhao; Kevin Kalinsky; Swarnali Acharyya
Journal:  Clin Med Insights Oncol       Date:  2016-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.